Carriers of cystic fibrosis may be at greater risk for allergic bronchopulmonary aspergillosis
Carriers of cystic fibrosis may be at greater risk for allergic bronchopulmonary aspergillosisTue, 10/09/2018 - 11:45News blog
In conclusion, a non-negligible proportion of patients with nonspecific alterations of screening tests at baseline may develop Aspergillus-associated syndromes during follow-up. Future studies are needed to confirm our observations.
Conclusion: Aspergillus categorizations using recommended definitions could not be confirmed in all patients. Using asp-specific T cell responses expand the aspergillus categories and enables to distinguish between allergic and infectious disease.
Kana Ram Jat, Pankaj C Vaidya, Joseph L Mathew, Sunil Jondhale, Meenu SinghLung India 2018 35(6):499-507 Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused by Aspergillus induced hypersensitivity. It usually occurs in immunocompetent but susceptible patients with bronchial asthma and cystic fibrosis. If ABPA goes undiagnosed and untreated, it may progress to bronchiectasis and/or pulmonary fibrosis with significant morbidity and mortality. ABPA is a well-recognized entity in adults; however, there is lack of literature in children. The aim of the present review is to summarize pathophysiology, di...
Glucocorticoids are the most widely used agents in the treatment of allergic bronchopulmonary aspergillosis (ABPA), a disorder characterised by immunologic reactions mounted against Aspergillus fumigatus colonising the airways of patients with asthma and cystic fibrosis [1, 2]. Unfortunately, the use of glucocorticoids is associated with several adverse reactions . A novel treatment strategy in ABPA would be the use of antifungal triazoles as monotherapy. Recently, we have shown that itraconazole was effective as monotherapy in acute-stage ABPA . Whether voriconazole monotherapy is also efficacious in acute-stage ABPA remains unknown.
Authors: Sehgal IS, Dhooria S, Behera D, Agarwal R Abstract Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that results from immune responses mounted against antigens of Aspergillus fumigatus, resulting in non-specific respiratory symptoms and structural lung damage. Classically defined in individuals suffering from bronchial asthma and cystic fibrosis, ABPA has recently been described in other lung diseases including COPD, pulmonary tuberculosis, idiopathic bronchiectasis and others. Herein, we report the first case of ABPA complicating Swyer-James-Macleod's syndrome that was successfully t...
Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a "research priorities" consensus statement for bronchiectasis. Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S–28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus species ...
Wednesday, July 18, 2018 - 13:02Slide presentation